synthetic biologics, inc. (nyse mkt: syn) is a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients. the company's lead candidates poised for phase 3 development are: (1) syn-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (ibs-c), and (2) syn-004 (ribaxamase) which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (iv) beta-lactam antibiotics for the prevention of c. difficile infection (cdi), antibiotic-associated diarrhea (aad) and the emergence of antimicrobial-resistance (amr). the company is also developing preclinical stage monoclonal antibody therapies for the prevention and treatment of pertussis and novel discovery stage biotherapeutics for the treatment of phenylketonuria (pku).
Company profile
Ticker
TOVX
Exchange
Website
CEO
Steven Shallcross
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ADEONA PHARMACEUTICALS, INC., PIPEX PHARMACEUTICALS, INC., SHEFFIELD MEDICAL TECHNOLOGIES INC, SHEFFIELD PHARMACEUTICALS INC, Synthetic Biologics, Inc.
SEC CIK
Corporate docs
Subsidiaries
Pipex Therapeutics, Inc. • Effective Pharmaceuticals, Inc. • Solovax, Inc. • CD4 Biosciences, Inc. • Epitope Pharmaceuticals, Inc. • Healthmine, Inc. • Putney Drug Corp. • Synthetic Biomics, Inc. • Theriva Biologics, S.L. ...
IRS number
133808303
TOVX stock data
Latest filings (excl ownership)
8-K
Regulation FD Disclosure
23 Apr 24
8-K
Regulation FD Disclosure
22 Apr 24
8-K
Regulation FD Disclosure
16 Apr 24
10-K
2023 FY
Annual report
25 Mar 24
8-K
Theriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial Results
25 Mar 24
8-K
Regulation FD Disclosure
7 Feb 24
8-K
Regulation FD Disclosure
8 Jan 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
Theriva™ Biologics Reports Third Quarter 2023 Operational Highlights and Financial Results
13 Nov 23
8-K
Regulation FD Disclosure
23 Oct 23
Transcripts
TOVX
Earnings call transcript
2023 Q3
13 Nov 23
TOVX
Earnings call transcript
2023 Q2
8 Aug 23
TOVX
Earnings call transcript
2023 Q1
11 May 23
TOVX
Earnings call transcript
2022 Q4
30 Mar 23
TOVX
Earnings call transcript
2022 Q3
10 Nov 22
TOVX
Earnings call transcript
2022 Q2
11 Aug 22
TOVX
Earnings call transcript
2022 Q2
11 Aug 22
TOVX
Earnings call transcript
2022 Q1
16 May 22
TOVX
Earnings call transcript
2022 Q1
16 May 22
TOVX
Earnings call transcript
2021 Q4
17 Mar 22
Latest ownership filings
4
STEVEN A SHALLCROSS
15 Dec 23
4
Jeffrey Alan Wolf
15 Dec 23
4
Jeffrey J Kraws
15 Dec 23
4
JOHN J MONAHAN
15 Dec 23
4
STEVEN A SHALLCROSS
8 Jun 23
4
STEVEN A SHALLCROSS
7 Jun 23
4
STEVEN A SHALLCROSS
13 Feb 23
4
STEVEN A SHALLCROSS
3 Feb 23
4
STEVEN A SHALLCROSS
26 Jan 23
4
STEVEN A SHALLCROSS
23 Jan 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 31.26 mm | 31.26 mm | 31.26 mm | 31.26 mm | 31.26 mm | 31.26 mm |
Cash burn (monthly) | 1.03 mm | 1.61 mm | 1.41 mm | 1.88 mm | 984.33 k | 1.49 mm |
Cash used (since last report) | 7.07 mm | 11.05 mm | 9.65 mm | 12.88 mm | 6.75 mm | 10.19 mm |
Cash remaining | 24.19 mm | 20.21 mm | 21.61 mm | 18.37 mm | 24.50 mm | 21.07 mm |
Runway (months of cash) | 23.5 | 12.5 | 15.4 | 9.8 | 24.9 | 14.2 |
Institutional ownership, Q3 2023
24.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 23 |
Opened positions | 4 |
Closed positions | 1 |
Increased positions | 4 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 546.02 mm |
Total shares | 4.20 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Custodian Ventures | 2.22 mm | $1.96 mm |
Iroquois Capital Management | 908.20 k | $247.00 k |
Vanguard | 512.76 k | $276.53 mm |
BLK Blackrock | 190.17 k | $102.56 mm |
Geode Capital Management | 141.17 k | $76.17 mm |
Renaissance Technologies | 54.21 k | $29.00 k |
STT State Street | 48.69 k | $26.26 mm |
Bridgeway Capital Management | 28.53 k | $15.39 mm |
NTRS Northern Trust | 26.60 k | $14.35 mm |
Jane Street | 17.33 k | $9.35 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
14 Dec 23 | Kraws Jeffrey J | Stock Options Common Stock | Grant | Acquire A | No | No | 0.5875 | 110,000 | 64.63 k | 110,000 |
14 Dec 23 | John J Monahan | Stock Options Common Stock | Grant | Acquire A | No | No | 0.5875 | 110,000 | 64.63 k | 110,000 |
14 Dec 23 | Wolf Jeffrey Alan | Stock Options Common Stock | Grant | Acquire A | No | No | 0.5875 | 110,000 | 64.63 k | 110,000 |
14 Dec 23 | Steven A Shallcross | Stock Options Common Stock | Grant | Acquire A | No | No | 0.5875 | 700,000 | 411.25 k | 700,000 |
7 Jun 23 | Steven A Shallcross | Common Stock | Buy | Acquire P | No | No | 0.6931 | 14,000 | 9.70 k | 250,000 |
News
Why Hibbett Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
23 Apr 24
Theriva Biologics FY EPS $(1.14) Beats $(1.28) Estimate; As Of December 31, 2023, Theriva Biologics Reports $23.2M In Cash, Which Is Expected To Provide Runway Into The First Quarter Of 2025
25 Mar 24
Earnings Scheduled For March 25, 2024
25 Mar 24
Preview: Theriva Biologics's Earnings
22 Mar 24
Theriva Biologics Granted EU Patent #3292142 For "Oncolytic Adenoviruses With Mutations In Immunodominant Adenovirus Epitopes And Their Use In Cancer Treatment"
20 Mar 24
Press releases
Theriva™ Biologics to Discuss the Trial Design for VIRAGE - a Phase 2b Clinical Study of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma - at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
25 Apr 24
Theriva Biologics Hits Several Milestones In 2023, Positioning Itself For Growth As The Firm Targets Difficult-To-Treat Cancers
17 Apr 24
Theriva™ Biologics Announces Presentation at the American Society for Cell and Gene Therapy 27th Annual Meeting
8 Apr 24
Theriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial Results
25 Mar 24
Theriva™ Biologics to Participate in the BIO-Europe Spring Conference
11 Mar 24